Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01256489
Recruitment Status : Withdrawn (Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis Syndrome (TENS) are rare (~3 in 1 million). No eligible subjects have been identified.)
First Posted : December 8, 2010
Last Update Posted : November 4, 2015
Information provided by (Responsible Party):
Massachusetts Eye and Ear Infirmary

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Actual Primary Completion Date : January 2015
  Actual Study Completion Date : January 2015